Hyderabad: Ferring Pharma to establish new manufacturing unit for Pentasa
Ferring will invest approximately €60M over the next 2-3 years for establishing this manufacturing facility.
Hyderabad: Ferring Pharma on Wednesday announced the establishment of another formulation unit in India at Hyderabad for manufacturing of its product called PENTASA (Mesalazine).This was announced after Telangana Industries Minister KT Rama Rao's meeting with leadership of Ferring - Alessandro Gilio, Executive Vice President and Chief Manufacturing and Supply Officer, Armin Metzger,...
Login or Register to read the full article
Hyderabad: Ferring Pharma on Wednesday announced the establishment of another formulation unit in India at Hyderabad for manufacturing of its product called PENTASA (Mesalazine).
This was announced after Telangana Industries Minister KT Rama Rao's meeting with leadership of Ferring - Alessandro Gilio, Executive Vice President and Chief Manufacturing and Supply Officer, Armin Metzger, Executive Vice President, Chief Scientific Officer, Francois Hosotte, Vice President Strategic Projects and Engineering and Bhavin Vaid, Senior Director, Corporate Communications at World Economic Forum, Davos.
Ferring will invest approximately €60M over the next 2-3 years for establishing this manufacturing facility.
PENTASA (Mesalazine) is a Ferring product used for the treatment and long-term management of inflammatory bowel diseases (IBD) including Ulcerative Colitis and Crohn's disease.
It is prescribed to treat the mild to moderate symptoms of active IBD as well as used widely as maintenance therapy to reduce the risk of recurrent attacks.
PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, with the exception of the US.
In the US, Shire US, Inc. sells PENTASA under a trademark license from Ferring.
Ferring produces the Active Pharmaceutical Ingredient (API), Mesalazine, at two of its state-of-the-art manufacturing facilities – in Denmark and in India, near Mumbai.
At present, Ferring has only one formulation unit for producing Pentasa in St. Prex, Switzerland and now Ferring has decided to establish another formulation unit at Hyderabad (Ferring Laboratories Pvt. Ltd.).
Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.
K.T Rama Rao said that, "I had the pleasure of inaugurating the facility only last month and just a month after, the company has decided to invest additional Eur 60 Mn based on their seamless experience of setting up their first facility in Hyderabad. This only reinstates the confidence global companies are reposing in Hyderabad's ecosystem and also a testament to the pro-business policies of Telangana Government."
Read also: Telangana Minister K T Rama Rao inaugrates Ferring Pharma Genome Valley facility
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd